This journal article by Dr. Frederic Larose and our frequent contributor Dr. Christine Chen compares various BTK inhibitors, and also provides comparison with and rationale for the continued use of Bendamustine + Rituximab in the Canadian context. No new research results are presented; the article is a summary of existing knowledge, and thus can be useful to those looking to refresh their knowledge about these drugs and their histories, and the place of the drugs in the Canadian healthcare system. .
- Current treatment landscape in Canada (very readable to the lay person)
- Molecular rationale for targeting Bruton’s tyrosine kinase in WM (the last paragraph is probably the most useful to the lay person)
- Clinical data supporting the use of Bruton’s tyrosine kinase inhibitors in WM (often technical; with subsections covering Ibrutinib, Zanubrutinib, Acalabrutinib, Tirabrutinib, and non-covalent BTK inhibitors including Pirtobrutinib (a.k.a. LOXO-305) and MK-1026 (a.k.a. AQR-531))
- Conclusion – Where do Bruton’s tyrosine kinase inhibitors fit in the Canadian treatment landscape (a useful summation, recommended reading)
Full text of the article is available at https://touchoncology.com/haematological-malignancies/journal-articles/brutons-tyrosine-kinase-inhibitors-for-the-treatment-of-waldenstroms-macroglobulinaemia-a-canadian-perspective/.